PATIENTS who have used proton pump inhibitors (PPIs) to treat digestive issues, and subsequently developed gastric cancer or kidney damage, are now being asked to register for a class action launched by Shine Lawyers.
The drugs that could involve an estimated 100,000 Australians in the investigation are: Nexium or Nexium 24HR (or drugs containing esomeprazole), Losec (omeprazole), Somac (pantoprazole), Pariet (rabeprazole) and Zoton FasTabs (lansoprazole).
PPIs are widely used for treating digestive symptoms by reducing stomach acid production.
However, they can increase the levels of gastrin, a hormone associated with the formation of cancer cells in the gastrointestinal and urinary tracts.
The manufacturers of the various drugs all declined to comment at this time, reported media.
For more details and to register for the class action, CLICK HERE. JG
The above article was sent to subscribers in Pharmacy Daily's issue from 09 Sep 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Sep 24
